1. Scrip
  2. >>R&D

Divided House On Challenge Trials For COVID-19 Vaccines But Collaboration Goals Unite

India Commits To Global Access Amid Vaccine Nationalism Concerns

 
• By Vibha Ravi and Anju Ghangurde

High-profile experts including Anthony Fauci and Adrian Hill share views at the ICMR symposium on progressing safe COVID-19 vaccines backed by ethical trials executed with appropriate scientific rigor. Human challenge studies, "vaccine nationalism" and equitable access were among the key issues deliberated, while India committed to making its coronavirus vaccines and related capabilities available to the world.  

Vaccine
India's Vaccine Manufacturing Strength Useful To The World • Source: Shutterstock

Amid mounting concern over the equitable distribution of COVID-19 vaccines, led by rising "vaccine nationalism" and deals by the US, UK, Japan and the EU to procure over a billion doses from leading developers, India has committed to make its vaccine arsenal and related capabilities available globally.

A symposium organized by the country’s top research body, the Indian Council of Medical Research (ICMR), opened with a video...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from R&D

More from Scrip

Novartis Chief Warns Of Fewer Launches And Drug Withdrawals In Europe

 
• By Kevin Grogan

Reimbursement rules are disincentivizing innovation, according to Vas Narasimhan.

Executives On The Move: Five New CEOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Ascentage Pharma, Inventiva and Brenig Therapeutics, plus five companies get new CFOs.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By Vibha Ravi

As AI-driven firms like Insilico, big pharma like J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s respectively advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?